scholarly journals Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction

2021 ◽  
Author(s):  
Hannah A. Blair
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction

scholarly journals Mildly symptomatic heart failure with reduced ejection fraction: diagnostic and therapeutic considerations

2020 ◽  
Vol 7 (4) ◽  
pp. 1477-1487
Author(s):  
Alexandra Arvanitaki ◽  
Eleni Michou ◽  
Andreas Kalogeropoulos ◽  
Haralambos Karvounis ◽  
George Giannakoulas
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction ◽  
Therapeutic Considerations

Pulmonary vascular response to exercise in symptomatic heart failure with reduced ejection fraction and pulmonary hypertension

2014 ◽  
Vol 17 (3) ◽  
pp. 320-328 ◽  
Author(s):  
Frederik H. Verbrugge ◽  
Matthias Dupont ◽  
Philippe B. Bertrand ◽  
Petra Nijst ◽  
Lars Grieten ◽  
...  
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
Ejection Fraction ◽  
Vascular Response ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction ◽  
Response To Exercise

scholarly journals The therapeutic role of ivabradine in heart failure

2018 ◽  
Vol 9 (11) ◽  
pp. 199-207 ◽  
Author(s):  
Charles Badu-Boateng ◽  
Robert Jennings ◽  
Daniel Hammersley
Keyword(s):  
Heart Failure ◽  
Heart Rate ◽  
Clinical Trials ◽  
Ejection Fraction ◽  
Sinoatrial Node ◽  
Review Article ◽  
Clinical Use ◽  
Symptomatic Heart Failure ◽  
Reduced Ejection Fraction

Heart failure represents a major global cause of morbidity and mortality. Ivabradine is a selective funny current (If) inhibitor, which acts on the sinoatrial node, resulting in a reduction in heart rate. Ivabradine is currently licensed for use in patients with symptomatic heart failure with reduced ejection fraction and a heart rate persistently at least 70 beats per minute in spite of otherwise optimal prognostic heart failure pharmacotherapy. In this review article, we examine the mechanism of action of ivabradine, evaluate the clinical trials underpinning its application in heart failure and discuss its current recommended clinical use in this capacity.

Sign in / Sign up

Export Citation Format

Share Document